Obinutuzumab induction and maintenance in patients with Waldenstrom macroglobulinaemia: an open-label, single-arm phase 2 study.

ABSTRACT:

Background

Despite progress in the treatment of Waldenström macroglobulinaemia, this disease still remains a therapeutic challenge, especially in older patients with multiple comorbidities. This study aimed to assess obinutuzumab single-agent induction and maintenance activity and safety in patients with relapsed or refractory Waldenström macroglobulinaemia.

Methods

This open-label, single-arm phase 2 study enrolled patients with relapsed or refractory Waldenström macroglobulinaemia with confirmed CD20 expression and measurable disease. Patients received an infusion of obinutuzumab 1000 mg on days 1, 8, and 15 during first cycle, followed by five more cycles with infusions on day 1. Patients with a response defined as stable disease or better at the end of the induction phas

SUBMITTER: Wrobel T 

PROVIDER: S-EPMC12318314 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature